These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 23463087)
1. Hyaluronic acid as a marker of sinusoidal obstruction syndrome after oxaliplatin-based chemotherapy for colorectal liver metastases: don't forget the tumor. Rahbari NN; Weitz J Ann Surg Oncol; 2013 May; 20(5):1405-7. PubMed ID: 23463087 [No Abstract] [Full Text] [Related]
2. Hyaluronic acid as a marker of hepatic sinusoidal obstruction syndrome secondary to oxaliplatin-based chemotherapy in patients with colorectal liver metastases. van den Broek MA; Vreuls CP; Winstanley A; Jansen RL; van Bijnen AA; Dello SA; Bemelmans MH; Dejong CH; Driessen A; Olde Damink SW Ann Surg Oncol; 2013 May; 20(5):1462-9. PubMed ID: 23463086 [TBL] [Abstract][Full Text] [Related]
3. Bevacizumab improves splenomegaly and decreases production of hyaluronic acid after L-OHP based chemotherapy. Arakawa Y; Shimada M; Utsunomiya T; Imura S; Morine Y; Ikemoto T; Hanaoka J; Kanamoto M; Iwahashi S; Saito Y; Yamada S; Asanoma M; Takasu C; Bando Y Anticancer Res; 2014 Apr; 34(4):1953-8. PubMed ID: 24692731 [TBL] [Abstract][Full Text] [Related]
4. Chemotherapy-induced Sinusoidal Injury (CSI) score: a novel histologic assessment of chemotherapy-related hepatic sinusoidal injury in patients with colorectal liver metastasis. Stevenson HL; Prats MM; Sasatomi E BMC Cancer; 2017 Jan; 17(1):35. PubMed ID: 28061766 [TBL] [Abstract][Full Text] [Related]
5. Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases. Klinger M; Eipeldauer S; Hacker S; Herberger B; Tamandl D; Dorfmeister M; Koelblinger C; Gruenberger B; Gruenberger T Eur J Surg Oncol; 2009 May; 35(5):515-20. PubMed ID: 19200687 [TBL] [Abstract][Full Text] [Related]
6. Hepatic sinusoidal obstruction syndrome reduces the effect of oxaliplatin in colorectal liver metastases. Robinson SM; White SA Histopathology; 2012 Dec; 61(6):1247-8. PubMed ID: 23043422 [No Abstract] [Full Text] [Related]
7. Hepatic Parenchymal Heterogeneity as a Marker for Oxaliplatin-Induced Sinusoidal Obstruction Syndrome: Correlation With Treatment Response of Colorectal Cancer Liver Metastases. Han NY; Park BJ; Yang KS; Kim MJ; Sung DJ; Sim KC; Cho SB AJR Am J Roentgenol; 2017 Nov; 209(5):1039-1045. PubMed ID: 28813196 [TBL] [Abstract][Full Text] [Related]
8. Hepatotoxicity following systemic therapy for colorectal liver metastases and the impact of chemotherapy-associated liver injury on outcomes after curative liver resection. Duwe G; Knitter S; Pesthy S; Beierle AS; Bahra M; Schmelzle M; Schmuck RB; Lohneis P; Raschzok N; Öllinger R; Sinn M; Struecker B; Sauer IM; Pratschke J; Andreou A Eur J Surg Oncol; 2017 Sep; 43(9):1668-1681. PubMed ID: 28599872 [TBL] [Abstract][Full Text] [Related]
9. Patterns of chemotherapy-induced hepatic injury and their implications for patients undergoing liver resection for colorectal liver metastases. Khan AZ; Morris-Stiff G; Makuuchi M J Hepatobiliary Pancreat Surg; 2009; 16(2):137-44. PubMed ID: 19093069 [TBL] [Abstract][Full Text] [Related]
11. Sinusoidal obstruction syndrome impairs long-term outcome of colorectal liver metastases treated with resection after neoadjuvant chemotherapy. Tamandl D; Klinger M; Eipeldauer S; Herberger B; Kaczirek K; Gruenberger B; Gruenberger T Ann Surg Oncol; 2011 Feb; 18(2):421-30. PubMed ID: 20844968 [TBL] [Abstract][Full Text] [Related]
12. Sinusoidal obstruction syndrome is a major feature of hepatic lesions associated with oxaliplatin neoadjuvant chemotherapy for liver colorectal metastases. Rubbia-Brandt L; Mentha G; Terris B J Am Coll Surg; 2006 Jan; 202(1):199-200. PubMed ID: 16377516 [No Abstract] [Full Text] [Related]
13. Splenic volume may be a useful indicator of the protective effect of bevacizumab against oxaliplatin-induced hepatic sinusoidal obstruction syndrome. Imai K; Emi Y; Iyama KI; Beppu T; Ogata Y; Kakeji Y; Samura H; Oki E; Akagi Y; Maehara Y; Baba H; Eur J Surg Oncol; 2014 May; 40(5):559-566. PubMed ID: 24388740 [TBL] [Abstract][Full Text] [Related]
14. Diagnostic performance of contrast-enhanced CT-scan in sinusoidal obstruction syndrome induced by chemotherapy of colorectal liver metastases: Radio-pathological correlation. Cayet S; Pasco J; Dujardin F; Besson M; Orain I; De Muret A; Miquelestorena-Standley E; Thiery J; Genet T; Le Bayon AG Eur J Radiol; 2017 Sep; 94():180-190. PubMed ID: 28712693 [TBL] [Abstract][Full Text] [Related]
15. Oxaliplatin-Induced Sinusoidal Obstruction Syndrome Masquerading as Colorectal Liver Metastasis: A Case Report. Gupta V; Chopde A; Patkar S; Deodhar K; Goel M J Gastrointest Cancer; 2023 Jun; 54(2):682-686. PubMed ID: 35666356 [TBL] [Abstract][Full Text] [Related]
16. Predicting high grade lesions of sinusoidal obstruction syndrome related to oxaliplatin-based chemotherapy for colorectal liver metastases: correlation with post-hepatectomy outcome. Soubrane O; Brouquet A; Zalinski S; Terris B; Brézault C; Mallet V; Goldwasser F; Scatton O Ann Surg; 2010 Mar; 251(3):454-60. PubMed ID: 20160638 [TBL] [Abstract][Full Text] [Related]
17. Sinusoidal obstruction syndrome after oxaliplatin-based chemotherapy. Seo AN; Kim H Clin Mol Hepatol; 2014 Mar; 20(1):81-4. PubMed ID: 24757663 [No Abstract] [Full Text] [Related]
18. [Hepatotoxicity of metastatic colorectal cancer chemotherapy: systematic review]. Baumgaertner I; Ratziu V; Vaillant JC; Hannoun L; Poynard T; André T Bull Cancer; 2010 May; 97(5):559-69. PubMed ID: 20167564 [TBL] [Abstract][Full Text] [Related]
19. Changes of liver hemodynamic and elastography parameters in patients with colorectal liver metastases receiving preoperative chemotherapy: "a note of caution". Pelegrina A; Martí J; Miquel R; Ferrer J; Hernández-Gea V; Diaz A; Nadal C; García-Valdecasas JC; Fuster J World J Surg Oncol; 2017 Dec; 15(1):224. PubMed ID: 29246174 [TBL] [Abstract][Full Text] [Related]
20. Serum hyaluronic acid in patients with veno-occlusive disease following bone marrow transplantation. Fried MW; Duncan A; Soroka S; Connaghan DG; Farrand A; Peter J; Strauss RM; Boyer TD; McDonald GB Bone Marrow Transplant; 2001 Mar; 27(6):635-9. PubMed ID: 11319594 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]